The ACS will likely not endorse our test directly (policy against showing favoritism to a product) but, believe me, thay can make known their displeasure with the PSA regimen and strongly state that another, newer test using biomarkers or a urine-based test shows greater promise. That's their way of naming us without really naming us...and the result will be the same as docs. will adopt the new test quickly.
Upon the adoption by Quest, likely within a short pewriod of time, those with analytical minds will begin to do---and see---the math. 25 MM US tests at $100 per equates to $2.5 Billion. A first year capture rate of only (ONLY) 10% means $250 Million in revs and net 10% to us is $25 Million. That's $.12 in EPS and we likely double EPS for the next 3-5 years as we gain market share and reach similar metrics outside the U.S. And these EPS numbers are recurring as the test needs to administered annually---at least that's what doc recommends with the PSA and the urine-based test will at least be comparably recommended.
And that's just the first of many tests, products, etc. that we should be able to roll out.
Market Data 
Markets 
AI
